The Efficacy of Pemigatinib in Advanced NSCLC With FGFR Aberration: Case Report

Clin Lung Cancer. 2024 Jan;25(1):e62-e66. doi: 10.1016/j.cllc.2023.10.005. Epub 2023 Oct 12.

Authors

Ming Gao¹, Lijie Wang¹, Fangfang Jing², Fan Zhang¹, Haitao Tao¹, Yi Hu³

Affiliations

¹ Department of Medical Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
² Department of Medical Oncology, The First Medical Center of PLA General Hospital, Beijing, China.
³ Department of Medical Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China. Electronic address: huyi301zlxb@sina.com.

PMID: 37940412
DOI: 10.1016/j.cllc.2023.10.005

No abstract available

Keywords: Advanced non-small cell lung cancer (NSCLC); Case report; Efficacy; Fibroblast growth factor receptor (FGFR) aberration; Pemigatinib.

Publication types

Case Reports

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Morpholines
Pyrimidines*
Pyrroles

Substances

pemigatinib
Pyrroles
Morpholines
Pyrimidines

Associated data

ChiCTR/ChiCTR2100049516